Extracting therapeutic antibodies from biological systems requires stringent purification processes. To reduce costs and accelerate development, novel strategies are essential ...

Nuclera has expanded its Series C funding round to USD $87 million following a new USD $12 million extension led by Elevage ...

The purification of proteins and antibodies is a critical process in biotechnology and pharmaceutical industries. Traditional methods often involve single-use materials, leading to high costs and ...

As therapeutic antibodies evolve, the industry is moving away from a one-size-fits-all chromatography approach. With an increasing share of non-traditional monoclonal antibodies (mAbs)—including ...

Antibody manufacturers should be encouraged to revisit older technologies as the industry moves towards continuous processing. That’s the view of Andrew Zydney, PhD, professor, chemical engineering, ...

Efficient purification of plasmids, proteins, and antibodies is critical for drug target identification, drug candidate development, and fundamental research. However, traditional column-based methods ...

This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates.

Nuclera has announced a $12million extension to its Series C round which raised $75m in October 2024. The raise was led by ...

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new research paper from its global research and development Center (R&D ...

Additional $12M financing led by Elevage Medical Technologies and Jonathan Milner alongside existing investors British ...